U.S. Viscosupplementation Market to Reach US$1.61 Bn by 2032, Says Persistence Market Research

The U.S. viscosupplementation market is poised for steady growth, with projections estimating its value to reach US$1,127.6 million by 2025, further expanding to US$1,611.7 million by 2032, registering a compound annual growth rate (CAGR) of 5.2% during the forecast period. This growth trajectory is underpinned by the rising prevalence of osteoarthritis (OA), a chronic and progressive joint disorder that affects over 32.5 million adults in the United States. As OA continues to be a significant source of morbidity and reduced quality of life, particularly among the aging and obese population, viscosupplementation has emerged as a vital non-surgical intervention strategy.

The historical market performance from 2019 to 2024 indicates a moderate CAGR of 4.4%, which reflects growing clinical adoption, increasing awareness, and incremental technological advancements. The trend towards minimally invasive outpatient solutions is accelerating demand across healthcare systems focused on cost-effectiveness, patient satisfaction, and improved clinical outcomes.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35654

Key Industry Highlights

Among product categories, single-injection viscosupplementation dominates the U.S. market, favored for its reduced treatment burden, lower frequency of clinic visits, and improved patient compliance. This is in contrast to multiple-injection regimens that may deter patient follow-up due to discomfort and time constraints.

Knee osteoarthritis continues to be the principal application segment, accounting for the majority of viscosupplementation procedures nationwide. With the knee bearing the brunt of daily biomechanical stress, the demand for localized, effective pain management solutions remains high.

A promising frontier lies in combination therapies that integrate hyaluronic acid (HA) with regenerative or anti-inflammatory agents such as platelet-rich plasma (PRP). These innovations are anticipated to expand therapeutic potential, enabling more comprehensive treatment regimens that not only lubricate joints but also address inflammation and cartilage regeneration.

Market Dynamics

Drivers

The primary driver of the U.S. viscosupplementation market is the increasing incidence of osteoarthritis, particularly among adults aged 55 to 74. An aging population, combined with lifestyle risk factors like obesity and sedentary behavior, continues to elevate the demand for effective joint preservation strategies. Viscosupplementation, offering pain relief and mobility enhancement without the need for surgery, aligns with both patient preferences and physician recommendations.

In addition, advancements in HA formulation, including cross-linked and high-molecular-weight variants, have improved viscosity, durability, and bioactivity of injections. These innovations are enhancing both the efficacy and longevity of symptom relief, expanding the patient base and broadening treatment windows.

Restraints

Despite its advantages, the viscosupplementation market faces competitive pressure from alternative therapies, particularly corticosteroid injections and physical therapy. Corticosteroids offer rapid relief at a lower cost, making them an attractive option for acute pain management, while physical therapy remains a cornerstone in non-pharmacologic OA treatment. Limited reimbursement policies and variable clinical guidelines across states further hinder market penetration, especially in cost-sensitive segments of the healthcare system.

Opportunities

There is significant opportunity in expanding viscosupplementation's role within ambulatory and outpatient care settings. The shift from inpatient to outpatient treatment is driven by efficiency gains, favorable insurance coverage, and increased patient satisfaction. Moreover, the integration of viscosupplementation into holistic joint care programs, including PRP, stem cell therapy, and targeted physical rehabilitation, offers a strong platform for innovation and product differentiation.

Emerging biomaterials and combination delivery platforms, such as HA-polymer composites, are another high-potential area, aimed at increasing HA stability, improving cartilage regeneration, and supporting controlled drug release mechanisms.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/us-viscosupplementation-market.asp

Category-wise Analysis

Product Insights

Single-injection therapies dominate the U.S. market landscape. The convenience of a single outpatient procedure over three to five weekly injections has significantly improved adherence and satisfaction among both patients and clinicians. Recent advancements in cross-linking technology allow for higher molecular weight HA that remains effective over longer periods, reinforcing the preference for single-dose regimens.

Application Insights

Knee osteoarthritis continues to account for the largest share of viscosupplementation procedures. With the knee being the most commonly affected joint due to mechanical loading and injury susceptibility, it presents the highest demand for pain-relieving, mobility-enhancing therapies. The high incidence among younger adults (under 65) also suggests a growing market for early intervention to delay the need for joint replacement.

Regional Insights

The U.S. remains the largest and most lucrative viscosupplementation market globally, driven by high OA prevalence, an advanced healthcare infrastructure, and favorable insurance coverage. States with aging populations, such as Florida, Pennsylvania, and California, are emerging as high-demand regions.

The trend toward outpatient care delivery is especially prominent in urban healthcare networks and orthopedic specialty clinics, where high patient turnover, streamlined care pathways, and specialized expertise align well with viscosupplementation treatment protocols. Rural regions are also beginning to adopt mobile outpatient models, increasing access to HA injections beyond urban centers.

Furthermore, research initiatives across U.S. universities and biotechnology firms are exploring the integration of HA with bioactive agents, including anti-inflammatory peptides, gene therapies, and PRP. These trials are setting the stage for the next generation of viscosupplementation products capable of delivering multifaceted therapeutic benefits.

Competitive Landscape

The U.S. viscosupplementation market is moderately consolidated, with key global and regional players operating across multiple product segments. Leading companies include Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Pharma USA Inc., and Seikagaku Corporation, each leveraging distinct strengths in product innovation, clinical data, and provider engagement.

Sanofi and Bioventus maintain robust portfolios through established brands and wide-reaching distribution networks, while Anika Therapeutics continues to lead in single-injection HA formulations and orthopedic R&D. Seikagaku Corporation is expanding its U.S. footprint through strategic partnerships, such as its 2025 co-development agreement with Ono Pharmaceutical for the Gel-One product.

Fidia Pharma USA and Ferring Pharmaceuticals remain aggressive in expanding their U.S. market presence through localized manufacturing and distribution initiatives. Meanwhile, emerging players like Searchlight Pharma and Aptissen GmbH are focusing on innovative delivery systems and extended-release HA formulations.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35654

Key Players in the U.S. Market

Sanofi S.A.
Zimmer Biomet Holdings Inc
Bioventus LLC
Anika Therapeutics Inc.
Fidia Pharma USA Inc.
Seikagaku Corporation
Ferring Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
OrthogenRx Inc.
Medical Device Business Services, Inc. (J&J)
Aptissen GmbH
TRB Chemedica International SA
AVNS

Searchlight Pharma Inc.

Market Segmentation

By Product:

Single Injection
Three Injections
Five Injections

By Application:

Knee Osteoarthritis
Hip Osteoarthritis
Others (Shoulder, Ankle, etc.)

By End User:

Hospitals
Ambulatory Surgical Centers
Orthopedic Clinics
Outpatient Facilities

Recent Developments

In April 2025, Seikagaku Corporation partnered with Ono Pharmaceutical to develop and commercialize a new formulation of Gel-One, utilizing proprietary cross-linked HA technology designed to extend therapeutic effects and improve patient outcomes.

In April 2024, BioSenic announced positive phase 3 clinical results for its late-stage investigational asset JTA-004, a novel single-injection treatment for knee OA, presented at the Osteoarthritis Research Society International conference. The data highlighted significant improvements in pain reduction and joint function with favorable safety outcomes.

Future Outlook

The future of the U.S. viscosupplementation market appears optimistic, with technology integration, biologic enhancements, and value-based care models expected to shape its evolution. As demand grows for minimally invasive, cost-effective treatments, viscosupplementation is likely to emerge as a cornerstone therapy in the multimodal management of OA.

Regulatory momentum toward wider reimbursement, increasing product approvals, and the growing emphasis on outpatient care will collectively accelerate market penetration. The continued investment in next-generation HA products, including combination therapies and bioengineered polymers, will offer competitive differentiation and clinical relevance.

Read More Related Reports:

Electrophysiology Ablation Market https://www.persistencemarketresearch.com/market-research/electrophysiology-ablation-market.asp
Generic Oncology Drugs Market https://www.persistencemarketresearch.com/market-research/generic-oncology-drugs-market.asp
Autosomal Dominant Polycystic Kidney Disease Treatment Market https://www.persistencemarketresearch.com/market-research/autosomal-dominant-polycystic-kidney-disease-treatment-market.asp
Facial Prosthetics Market https://www.persistencemarketresearch.com/market-research/facial-prosthetics-market.asp
Liquid Embolic Market https://www.persistencemarketresearch.com/market-research/liquid-embolic-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.